| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,630,000,000 |
| Market
Cap: |
534.07(B) |
| Last
Volume: |
10,609,729 |
Avg
Vol: |
8,221,786 |
| 52
Week Range: |
$142.06 - $203.07 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
| |
S&P COMPOSITE 1500 |
|
DOW JONES COMPOSITE |
| |
DOW JONES INDUSTRIAL AVERAGE |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
| |
MAJOR MARKET |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 29 |
| Guru Rank Value : 17.2 |
| Guru Occurances : 6 |
|
|
|
|
|
| |
|
Company Profile Johnson & Johnson is a holding company. Through its subsidiaries, Co. is engaged in the research and development, manufacture and sale of products in the health care field. Co. has three business segments: Consumer Health, which includes products focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension; and Medical Devices, which includes products used in the Interventional Solutions, Orthopaedics, Surgery, and Vision fields.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
| Total Buy Value |
$0 |
$0 |
$147,220 |
$147,220 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
204,016 |
239,973 |
260,390 |
334,313 |
| Total Sell Value |
$36,775,331 |
$42,880,732 |
$46,107,532 |
$57,761,379 |
| Total People Sold |
3 |
4 |
6 |
7 |
| Total Sell Transactions |
3 |
5 |
8 |
11 |
| End Date |
2025-08-21 |
2025-05-20 |
2024-11-19 |
2023-11-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
Reed John C |
EVP, Innovative Medicine, R&D |
|
2025-10-17 |
4 |
S |
$192.71 |
$4,185,793 |
D/D |
(21,721) |
10,658 |
|
-5% |
|
Reed John C |
EVP, Innovative Medicine, R&D |
|
2025-10-17 |
4 |
OE |
$157.92 |
$3,430,180 |
D/D |
21,721 |
32,379 |
|
- |
|
Taubert Jennifer L |
EVP, WWC. Innovative Medicine |
|
2025-09-04 |
4 |
S |
$177.81 |
$10,040,883 |
D/D |
(56,471) |
178,013 |
|
-13% |
|
Taubert Jennifer L |
EVP, WWC. Innovative Medicine |
|
2025-09-04 |
4 |
OE |
$101.87 |
$5,752,701 |
D/D |
56,471 |
234,484 |
|
- |
|
Forminard Elizabeth |
Executive VP, General Counsel |
|
2025-08-29 |
4 |
D |
$177.20 |
$1,695,804 |
D/D |
(9,570) |
12,853 |
|
- |
|
Forminard Elizabeth |
Executive VP, General Counsel |
|
2025-08-29 |
4 |
OE |
$115.67 |
$1,332,634 |
D/D |
11,521 |
22,423 |
|
- |
|
Duato Joaquin |
CEO and Chairman of the Board |
|
2025-08-22 |
4 |
S |
$179.21 |
$22,548,655 |
D/D |
(125,824) |
275,967 |
|
-13% |
|
Duato Joaquin |
CEO and Chairman of the Board |
|
2025-08-22 |
4 |
OE |
$101.87 |
$12,817,691 |
D/D |
125,824 |
401,791 |
|
- |
|
Wolk Joseph J |
Exec VP, CFO |
|
2025-08-15 |
4 |
S |
$176.91 |
$2,975,571 |
D/D |
(16,820) |
14,000 |
|
-15% |
|
Wolk Joseph J |
Exec VP, CFO |
|
2025-08-15 |
4 |
OE |
$101.87 |
$1,713,453 |
D/D |
16,820 |
30,820 |
|
- |
|
Reed John C |
EVP, Innovative Medicine, R&D |
|
2025-07-17 |
4 |
S |
$163.55 |
$3,129,830 |
D/D |
(19,137) |
10,658 |
|
-24% |
|
Reed John C |
EVP, Innovative Medicine, R&D |
|
2025-05-01 |
4 |
D |
$156.31 |
$1,719,723 |
D/D |
(11,002) |
29,795 |
|
- |
|
Reed John C |
EVP, Innovative Medicine, R&D |
|
2025-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,255 |
40,797 |
|
- |
|
Duato Joaquin |
CEO and Chairman of the Board |
|
2025-03-18 |
4 |
GA |
$0.00 |
$0 |
I/I |
130,852 |
130,852 |
|
- |
|
Duato Joaquin |
CEO and Chairman of the Board |
|
2025-03-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
130,852 |
275,967 |
|
- |
|
Decker Robert J |
VP Corporate Controller |
|
2025-02-25 |
4 |
S |
$165.88 |
$1,160,994 |
D/D |
(6,999) |
21,001 |
|
7% |
|
Decker Robert J |
VP Corporate Controller |
|
2025-02-25 |
4 |
OE |
$101.87 |
$712,988 |
D/D |
6,999 |
28,000 |
|
- |
|
Wolk Joseph J |
Exec VP, CFO |
|
2025-02-18 |
4 |
D |
$156.15 |
$119,923 |
D/D |
(768) |
5,345 |
|
- |
|
Duato Joaquin |
CEO and Chairman of the Board |
|
2025-02-18 |
4 |
D |
$156.15 |
$250,152 |
D/D |
(1,602) |
395,923 |
|
- |
|
Mulholland Kristen |
EVP, Chief HR Officer |
|
2025-02-18 |
4 |
D |
$156.15 |
$18,738 |
D/D |
(120) |
12,975 |
|
- |
|
Swanson James D. |
EVP, CIO |
|
2025-02-18 |
4 |
D |
$156.15 |
$22,017 |
D/D |
(141) |
16,621 |
|
- |
|
Taubert Jennifer L |
EVP, WWC. Innovative Medicine |
|
2025-02-18 |
4 |
D |
$156.15 |
$101,654 |
D/D |
(651) |
170,459 |
|
- |
|
Broadhurst Vanessa |
EVP, Global Corp Affairs |
|
2025-02-18 |
4 |
D |
$156.15 |
$24,672 |
D/D |
(158) |
21,681 |
|
- |
|
Decker Robert J |
VP Corporate Controller |
|
2025-02-18 |
4 |
D |
$156.15 |
$14,678 |
D/D |
(94) |
20,022 |
|
- |
|
Reed John C |
EVP, Innovative Medicine, R&D |
|
2025-02-18 |
4 |
D |
$156.15 |
$60,118 |
D/D |
(385) |
15,542 |
|
- |
|
643 Records found
|
|
Page 1 of 26 |
|
|